Abbott Laboratories: Company Analysis

Product Type: Report (41 pages)	Published by: Datamonitor	Single user price: $5700.00
Product Code: HC00068-001	Published on: 08 August 2012	Multi-user price: $14250.00

This analysis examines the historical and forecast performance for Abbott in the prescription pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs.

Scope of this research

- Gain insight into Abbott's strategic outlook across the next 6 years
- Analyze company sales forecasts by product, therapy area, lifecycle stage, geography, molecule type and source.

Research and analysis highlights

Strategic insight into the prospects for Abbott over the next six years. Picking out key strengths, weaknesses, opportunities and threats and evaluating the company's prescription pharmaceuticals outlook using a variety of cuts of the historical and forecast sales.

Key reasons to purchase this research

- Benchmark Abbott's performance against key rivals in the prescription pharmaceutical sector
- Examine how the spun out pharmaceuticals company Abbvie will fare as a standalone unit
- Discover how Abbott has utilized M&A to become one of the world's largest multi-disciplinary healthcare companies

Abbott Laboratories: Company Analysis

Product Type: Report (41 pages)
Product Code: HC00068-001
Published by: Datamonitor
Published on: 08 August 2012
Single user price: $5700.00
Multi-user price: $14250.00

Table of contents

SCOPE OF ABBOTT ANALYSIS
- PharmaVitae Explorer database
- Analysis structure
  - Executive summary
  - Strategic insight
  - Company overview
  - Operating performance analysis
- Data sourcing
  - Analyst consensus

EXECUTIVE SUMMARY
- Key findings
- Abbott prescription pharmaceutical sales outlook
- Abbott financial outlook
- SWOT analysis
  - Strengths
  - Weaknesses
  - Opportunities
  - Threats

STRATEGIC INSIGHT
- Launch/core/expiry analysis
- M&A dictates Abbott's corporate strategy in run-up to AbbVie separation
  - Indian market expansion
- Abbott has the leading share of the lucrative autoimmune disorder market
  - Abbott's heavy reliance on Humira continues
- Weak pipeline undermines growth expectations
- Innovative pharma split imminent

COMPANY OVERVIEW
- Key findings
- Background
- Corporate structure
  - Pharmaceuticals
  - Nutritionals
  - Diagnostics
  - Vascular
  - Other
- M&A history
  - M&A strategy

OPERATING PERFORMANCE ANALYSIS
- Key findings
- Reconciliation between PharmaVitae-formatted prescription pharma sales and company-reported total sales, 2005–11

Abbott Laboratories: Company Analysis

Product Type: Report (41 pages)
Product Code: HC00068-001
Published by: Datamonitor
Published on: 08 August 2012
Single user price: $5700.00
Multi-user price: $14250.00

Operating costs and profit analysis
Operating costs and profit analysis, 2005–11
Operating cost and profit analysis, 2011–17
APPENDIX
Exchange rates
TABLES
Table: Datamonitor's established pharmaceutical company coverage, 2012
Table: Abbott – key product overview ($m), 2011–17
Table: Abbott's financial performance ($m), 2011–17
Table: Abbott launch, core, and expiry portfolio overview ($m), 2011–17
Table: AbbVie product portfolio sales ($m), 2011–17
Table: AbbVie operating performance ($m), 2011–17
Table: Abbott key merger and acquisition deals, 2001–11
Table: Total Abbott sales by business unit ($m), 2005–11
Table: Abbott operating revenue/cost analysis ($m), 2005–11
Table: Abbott operating cost ratio analysis (percentage of total revenues), 2005–11
Table: Abbott operating revenue/cost analysis ($m), 2011–17
Table: Abbott operating cost ratio analysis (percentage of total revenues), 2011–17
Table: Exchange rates, 2012
FIGURES
Figure: The PharmaVitae Explorer
Figure: Abbott's prescription pharmaceutical performance, sales ($m) and growth rate (%), 2005–17
Figure: Abbott's financial performance ($m), 2005–17
Figure: Abbott launch/core/expiry configuration ($m), 2011–17
Figure: Leading companies in the immunology and inflammation biologics space (%), 2005–17
Figure: Abbott operating revenue/cost analysis ($m), 2005–17

Abbott Laboratories: Company Analysis

Product Type: Report (41 pages)	Published by: Datamonitor	Single user price: $5700.00
Product Code: HC00068-001	Published on: 08 August 2012	Multi-user price: $14250.00

YES, I WOULD LIKE TO PURCHASE NOW

Fax back this form to

+1 646 365 3362 (Americas) +61 2 8705 6901 (Asia Pacific) +44 20 7990 9988 (Europe)

Please select the licence type (learn more)

☐ $5700.00 (Single user licence) ☐ $14250.00 (multi-user licence)

Complete your details

Title Mr ☐ Mrs ☐ Ms ☐

Name _____

Job Title _____

Department _____

Company _____

Address _____

State/Province _____

Country _____ Post Code/ZIP _____

Email _____

Tel _____ Fax _____

Please sign below to confirm your order

_____

Date _____

Complete payment details

☐ Tick here to confirm you wish to be invoiced for this item
Please supply purchase order number or enter N/A:

If you are an EU company (except UK) please supply your VAT / BTW/ MOMS / MWST/ IVA / FPA number

If you wish to pay by credit card please complete your purchase online
Or call us on:
+44 161 238 4085 (EU)
+61 2 8705 6900 (AP)
+1 212 686 7400 (US)
Please do not add any credit card details on this form

This product is delivered in electronic format. If you require hard copy format please contact us.
To view the terms and conditions related to the sale of this product please click here.